Creathor News

Germanys High Profile Online Real Estate Investment Platform iFunded Raises 4 Million Euro Growth Capital To Extend Its Offer To Institutional Investors And To Integrate Blockchain Technology.

September 25, 2018

Berlin, 25.09.2018 – iFunded, one of Germanys leading digital real estate investment platforms and the first to offer investments to institutional investors, announces a 4 million Euro Pre-Series A round of financing led by EVAN Group plc. along with former head of sales and managing director Citibank Fixed Income Asia, Torsten Pfeifer, now CEO Real ... Read More


CEVEC strengthens its Scientific Advisory Board with the appointment of Gene Therapy Specialist J. Fraser Wright, Ph.D.

June 28, 2018

Wright is a widely recognized worldwide expert in the fields of gene therapy and adeno associated viral (AAV) vectors with more than 20 years of experience in industry and academic settings. Wright’s appointment completes CEVEC’s CAP®GT Scientific Advisory Board, implemented to support CEVEC in its goal establishing CAP®GT as the industry standard for scalable production of viral gene therapy vectors. … Read More


Creathor Ventures invests in decentralised database start-up Haja Networks

June 12, 2018

Creathor Ventures becomes an investor in Haja Networks, joining Outlier Ventures and Polychain Capital. The funding round also features Berlin-based BigchainDB. Haja Networks is an ambitious start-up comprised of some of the early team behind OrbitDB and IPFS that is building two new and complementary open-source protocols to enable decentralised databases. … Read More


AYOXXA launches LUNARIS™ Human & Mouse 6-Plex T Cell Characterization Kits to elucidate T cell differentiation

June 4, 2018

AYOXXA Biosystems GmbH, an international biotechnology company offering a range of products and services which enable advances in translational proteomics, today announced the expansion of its catalogue of kits for fully scalable multiplex protein analysis with the introduction of LUNARIS™ Human & Mouse 6-Plex T Cell Characterization Kits. The Kits are validated for quantitative analysis of soluble effector molecules secreted by distinct T cell populations that serve as biomarkers for specific population subsets. The kit enables translational research in areas including immune response biology, autoimmune disorders and cancer using murine and human samples. … Read More


Creathor invests in German biotech company Acousia to fight hearing loss in EUR 10 million financing round

May 14, 2018

Creathor Ventures announced today that it has, together with other investors, invested around EUR 10 million in a Series B investment round in Acousia Therapeutics GmbH. Acousia is a Tübingen/Germany-based leader in the discovery and development of novel therapies in inner ear related diseases and pathologies. Thebiotechnology company has developed drug candidates that will protect, repair and restore sensory hair cell function in patients suffering from hearing loss, caused by ototoxic drugs, normal aging process, noise and other conditions like sudden deafness. … Read More


CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP®Go technology

May 11, 2018

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP®Go technology. … Read More


From phenotype to diagnosis: Blueprint Genetics launches an open digital platform to connect clinicians based on matching rare variants

April 19, 2018

The aim of the Nucleus Connecting Clinicians Open platform is to make rare genomic data accessible to health care professionals around the world. This platform provides them with the opportunity to share knowledge and phenotypes for rare disease patients with a Variant of Uncertain Significance (VUS) and Likely Pathogenic variants. … Read More


Creathor Ventures joins SICTIC

April 18, 2018

Swiss startups may look forward to larger sums in their seed financing rounds. Creathor Ventures with over EUR 230 million under management has joined the Swiss ICT Investor Club (SICTIC) as preferred co-investor. … Read More


Creathor invests in ehealth platform „HUMANOO“

January 30, 2018

Berlin/Bad Homburg v.d.H., January 30, 2017 – Creathor Ventures, together with Dieter von Holtzbrinck Ventures (DvH Ventures), Rheingau Founders, Rocket Internet and other investors, invests a significant seven-digit amount in HUMANOO, the Berlin-based provider of a digital health companion for employees and insured persons. HUMANOO intends to use the cash infusion to further expand the ... Read More


SIRION Biotech and Acucela Set Sights on Gene Delivery Tools for Ocular Gene Therapy

January 9, 2018

SIRION Biotech GmbH (“SIRION”), a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced today that it signed a two year development agreement with Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy. … Read More


Wunderflats closes €3 million investment and establishes “Housing as a Service”

November 16, 2017

The number of furnished apartments in Germany has doubled within the last 4 years1. In order to enable easy renting and letting of these apartments online, Jan Hase and Arkadi Jampolski founded the property tech company Wunderflats in 2015. … Read More


Up to 70% efficiency gain possible: Deloitte examines the efficiency potential of tenant apps for the housing industry based on data provided by Allthings

October 2, 2017

Tenant apps are not only designed to improve tenant communication and achieve a corresponding boost in customer satisfaction, but to optimize workflows as well. Deloitte uses a model calculation to examine whether tenant apps can increase process efficiency in housing companies. The results, which are based anonymized usage data from Allthings, reveal time savings of up to 70%. … Read More


Allthings also to implement digital solution at business properties of Credit Suisse Global Real Estate

September 28, 2017

In March 2017 the Global Real Estate group of Credit Suisse Asset Management (Schweiz) AG decided to have its entire service portfolio from the LIVING SERVICES residential segment presented via the Allthings platform. Now, for the first time, an individually tailored service app will be implemented at four of their large business properties as well. Some 4,000 employees from companies in different regions of Switzerland will soon be able to use a multitude of digital services through the mobile application. … Read More


AYOXXA launches LUNARIS Mouse 12-Plex Th17 Kit to elucidate Th17 cell biology

September 22, 2017

LUNARIS™ Mouse 12-Plex Th17 Kit comprises highly specific reagents for the quantitative analysis of soluble markers of Th17 cell biology Kit includes the primary Th17 related cytokines involved in autoimmune disorders, immune-mediated diseases as well as asthma, allergy, cancer, microbial defense and transplantation Launch marks a further step in establishing AYOXXA’s LUNARIS™ as the technology ... Read More


Wir beobachten das Zusammenwachsen von Software und Medizin

September 21, 2017

Mit der steigenden Digitalisierung der Medizin und neuen Konzepten wie Next Generation Sequenzierungstechnologien (NGS) und Artificial Intelligence (AI) beobachten wir das immer stärkere Zusammenwachsen von Software und Medizin. … Read More


Creathor Venture invests in AI-enabled clinical genetic testing company Blueprint Genetics as part of an up to € 14 million financing round

July 11, 2017

Creathor Venture announced today that it is leading a financing round for Helsinki, Finland-based Blueprint Genetics. The company is an internationally successful provider of clinical genetic testing for the diagnosis of inherited diseases, leveraging a proprietary AI-enabled sequencing and interpretation platform. The start-up will receive a total of up to € 14 million from an international syndicate of investors. The financing round is led by new investors Creathor Venture and MedTech Innovation Partners (MTIP), while existing investors Inventure and Pontos Group are participating as well. … Read More


Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I

July 10, 2017

Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases. … Read More


Creathor Venture strengthens management team, appoints three new Partners

June 21, 2017

Bad Homburg v.d.H., June 21st, 2017 – Creathor Venture, leading European venture capital firm, has promoted three of its long-time Investment Managers to Partners effective June 1st, 2017. Christian Leikert, Dr Christian Weiss and Christian Weniger complement Creathor’s management team, joining CEO Dr Gert Köhler and Managing Partners Karlheinz Schmelig and Cédric Köhler. With the ... Read More


Creathor Venture and private investors invest CHF 2.5 million in PropTech company Allthings

June 20, 2017

Creathor Venture, a leading pan-European venture capital firm, together with a circle of experienced private investors from the real estate industry invest CHF 2.5 million in German-Swiss property tech company Allthings Technologies AG. … Read More


Personalisierte Medizin: Der Blick durch die VC-Brille

June 1, 2017

Jahr für Jahr werden Milliarden von Euro für Medikamente verschwendet, die keinen Effekt im Patienten haben. Doch seit Regulierungsbehörden die Entwicklung von Biomarkern zur Voraussetzung für die Zulassung neuer Medikamente machen (Companion Diagnostic) und Pharmafirmen sehr hohe Preise für ihre ­innovativsten Behandlungen in den Zielsegmenten durchsetzen können, gelingt der personalisierten Medizin Schritt für Schritt der ­Durchbruch. … Read More


Artificial Intelligence Is The Buzzword Of 2017, Says Creathor Venture’s Managing Partner

May 23, 2017

Cédric Köhler, Managing Partner at Creathor Venture, a pan-European fund currently managing more than EUR 220 million, talks about their most successful investment so far and explains why Artificial Intelligence is 2017's buzzword in an interview with Susi Wallner from StartUs magazine. … Read More


CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

May 17, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will collaborate with PlasmidFactory, the leading contract manufacturer and service provider for plasmid and minicircle DNA. … Read More


Creathor Venture invests 1.5 million euros in Swedish high-tech start-up Adaptive Simulations together with another investor

May 4, 2017

Creathor Venture, leading European venture capital firm in the high-tech space, announced today that they invest 1.5 million euros in Adaptive Simulations together with Estonian VC Karma Ventures. Adaptive Simulations is a spin-out of highly ranked tech-university KTH Royal Institute of Technology in Stockholm. … Read More


“We have proven that we help our start-ups across the finish line”

April 21, 2017

“For more than seven fund generations, our focus has been on tech and life sciences now as well as on the constantly increasing intersection of these two areas (e.g., digital health). There are not many VCs in Europe who can do both.” Creathor Venture’s Managing Partner Cédric Köhler talks about Creathor’s strategy in Berlin Valley’s series of short start-up portraits. … Read More


The marathon trade sale exit of Sividon

April 21, 2017

"The trade sale of Sividon to Myriad was the result of some kind of a marathon run consisting of years of negotiations and two M & A processes at the end of which the selling price was more than 100 percent above the first offer." Creathor Venture’s Managing Partner Karlheinz Schmelig writes about the long Sividon exit in Ernst & Young's annual German biotech report “Spot on Innovation!”. … Read More


“In the end, venture capital is something religious”

April 21, 2017

"We see ourselves as a very active and dedicated partner. We have the know-how and a network of more than 30 years in the venture capital sector to support our portfolio companies," says Cédric Köhler, Managing Partner at Creathor Venture, in an interview with … Read More


Karlheinz Schmelig speaks about Creathor’s investment focus at Nordic Private Capital Day 2017

March 31, 2017

Our Managing Partner Karlheinz Schmelig speaks about the changing dynamics in private equity, venture capital and Creathor's investment focus in an interview at Nordic Private Capital Day 2017 in Stockholm. … Read More


CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology

March 16, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. … Read More


R3Coms selected to join Startup Autobahn Program #2

February 27, 2017

Berlin, February 21st, 2017 – R3Coms, the R3 – Reliable Realtime Radio Communications GmbH, has been selected by the jury of Startup Autobahn to take part in its Program #2 starting in March 2017. The decision was made after the participation of R3Coms in the Startup Autobahn Selection Day earlier this month. In this new ... Read More


CEVEC licenses CAP® technologies for the development and commercialization of vaccines against Zika Virus infections

February 9, 2017

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development Cologne, Germany, February 09, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with ... Read More


Creathor Venture and IBB Beteiligungsgesellschaft invest a seven-digit amount in manufacturer of ultra-reliable communication systems R3 Communications

January 23, 2017

Berlin/Bad Homburg v.d.H., January 23, 2017 – Creathor Venture, one of the leading European venture capital firms,together withVC FondsTechnologie Berlin, managed by IBB Beteiligungsgesellschaft, joins Berlin high-tech start-up R3 Communications as a partner. The investment is part of a pre-seriesA financing round. R3 Communications, founded in July 2015, develops ultra-reliable real-time communication systems that are ... Read More


Breakthrough technology of Sirion Biotech improves genetic stem cell therapies

January 13, 2017

(Martinsried, 12.01.2017) With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechnology in Martinsried/Planegg near Munich, reports an annual growth of 140% to 4 million Euros in revenue, and profitability – just in time to celebrate its 10th year in the business. Decisive for this ... Read More


Creathor Venture portfolio-company Phenex receives 100 M USD Milestone Payment from Gilead

January 5, 2017

Ludwigshafen, Germany, January 06, 2017 – Phenex Pharmaceuticals AG (Phenex) yesterday announced that the company has received a 100 M USD milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A., for its program with GS-9674 targeting nonalcoholic steatohepatitis (NASH). GS-9674 is a novel, synthetic and nonsteroidal FXR agonist which was originally developed by ... Read More


Interview with Karlheinz Schmelig at Bio-Europe 2016

December 7, 2016

Video interview with our Managing Partner Karlheinz Schmelig at Bio-Europe 2016 in Cologne. … Read More


CEVEC submits Biologics Master File (BB-MF) for CAP® Technology to the U.S. FDA

October 27, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that is has submitted a Biologics Master File (BB-MF) for its human cell substrate CAP® to the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). … Read More


Creathor Venture leads € 2.6 million financing round in rental car comparison site HAPPYCAR

October 7, 2016

Creathor Venture, one of the leading European Venture Capital firms, leads a new financing round in the rental car comparison site HAPPYCAR. Creathor Venture as well as the other existing investors HR Ventures, Capnamic Ventures, NWZ Digital and TruVenturo participated in the € 2.6 million financing round. … Read More


Creathor Venture invests a seven digit amount in the real estate crowdinvesting platform iFunded

September 30, 2016

“Creathor’s investment confirms our strategy and the strong position iFunded has established as a real estate crowdinvesting platform,” says Michael Stephan, founder and CEO of The platform allows both private and institutional investors to invest alongside real estate experts directly in the real estate projects of their choice. … Read More


Iconicfuture appoints new dynamic management duo

August 30, 2016

Johannes-Philipp Berendes and Moritz Burmeister have been named new Managing Directors at Iconicfuture. With a lean and entrepreneurial business approach the two young managers aim to make the company more flexible and agile to operate successfully in the rapidly changing games market. … Read More


AYOXXA and Märzhäuser introduce a benchtop device for Protein Multiplex Analysis

August 22, 2016

AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined forces to develop a dedicated benchtop device for the analysis of LUNARIS™ Multiplex assays. The AYOXXA Reader AR01 expands the technology platform to offer researchers a complete, flexible and user-friendly system for multiprotein analysis. The device was approved for routine laboratory work use in biomedical research. … Read More


News Republic, a portfolio-company of Creathor Venture, successfully sold to Cheetah Mobile Inc. (NYSE: CMCM)

August 8, 2016

Bad Homburg v.d.H., August 8th, 2016 – Creathor Venture, a leading pan-European Venture Capital firm, successfully sold its portfolio company News Republic, a worldwide leading global mobile news service operator for US$ 57 million. News Republic is an international mobile company focusing on changing the news ecosystem and the way people interact with the world ... Read More


Learn more about Creathor’s DNA: Dr. Gert Köhler in an interview with HBH Investor Talks

July 6, 2016

Founded by Gert Köhler, the company has funded over 200 companies, and currently holds a portfolio of 35 startups. With close to 180 million in assets, the fund works with businesses in social media and networks, TV technology, shared economy, fintech, software, cloud computing, mobile health and personalised medicine, adjusting their lines of business depending on market trends. [...] … Read More


Creathor Venture leads Series B financing round of € 5.2 million in CryoTherapeutics

July 6, 2016

Creathor Venture, one of the leading European Venture Capital firms, leads a Series B financing round in CryoTherapeutics, the developer of a proprietary cryotherapy system for use in the treatment of coronary artery disease. The life science start-up CryoTherapeutics receives at total of € 5.2 million in the current Series B financing round from Creathor Venture as well as from the existing investors NRW.BANK, Peppermint CBF, High-Tech Gründerfonds (HTGF), Getz Brothers, Kreditanstalt für Wiederaufbau (KfW) and several renowned business angels. … Read More


Matthew Beck, Greg Carroll and Rahul Bathia join video intelligence in new London office

July 1, 2016

A Zurich-based martech company, has opened its London office in Paddington and expanded its team to include Matthew Beck, Greg Carroll and Rahul Bathia. … Read More


CEVEC further strengthens organization to drive industrialization and commercialization of CAP® technologies

July 1, 2016

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a strengthening of the Company reflective of its strategic progress. … Read More


A Perfect Match: Caprotec bioanalytics collaborates with Charles River

June 29, 2016

A strategic collaboration between caprotec bioanalytics and Charles River has been established to offer their proprietary protein capture technology for phenotypic screening target deconvolution. … Read More


Interview with on the Sividon transaction

June 16, 2016

Sividon was a spin-off from Siemens, founded in July 2011 – and it was just sold to the American Myriad Genetics ($2.2Bn market cap) for €50M, even though the company raised only €5M over its lifetime. Philip Hemme (Co-Founder & CEO of discussed this success story with Karlheinz Schmelig, partner of Sividon’s Lead investor Creathor Venture. ... Read More


Creathor Venture sells its shares in Sividon Diagnostics to Myriad Genetics as part of a transaction valued up to €50 million

June 1, 2016

Creathor Venture, one of the leading European Venture Capital firms, sells its shares in Sividon Diagnostics GmbH, the developer of the EndoPredict® test, to Myriad Genetics, Inc. (NASDAQ: MYGN). The financial terms for the transaction were €50 million incl. performance-based milestone payments for 100% of Sividon’s share capital. … Read More


Creathor Venture sells its stake in stylefruits to Ströer

April 27, 2016

Creathor Venture, one of the leading European Venture Capital firms, sells its stake in stylefruits GmbH, the European wide popular social commerce platform for fashion and living, to Ströer Content Group GmbH. … Read More


Knip AG acquired financial expert of Ringier Axel Springer Media AG

April 18, 2016

The Fintech company Knip reinforces its management team: Emily Kruse joined Knip AG as CFO in April 2016. … Read More


Europe’s hottest fintech start-ups named in the fintech50 2016

April 14, 2016

KNIP, a mobile digital Insurance manager, has been selected as one of the FinTech50 2016 companies. More than 1200 companies across Europe aimed for this award. The jury consists of the biggest names in FinTech. … Read More


Knip wins Swiss FinTech Award

March 31, 2016

The Swiss FinTech Award has been initiated by the Finanz und Wirtschaft Forum located in Zurich. Thursday night, the first Swiss FinTech Award has been granted to the two most promising and convincing Swiss Fintech-solutions Knip and Sentifi. … Read More


Viewster Ranks No. 10 on the 2016 Inc. 5000 Europe List

March 2, 2016

Inc. magazine ranked Viewster No. 10 on the 2016 Inc. 5000 list of fastest growing private companies in Europe and testifies Viewster a growth of 1,551% over the past three years. Average Growth Rate of Inc. 5000 Europe Companies is 226+% with Annual Revenue of €110 Billion. … Read More


More Retailers to Join Apple TV Market with Shopgate’s Retail Platform

March 1, 2016

AUSTIN, Texas–(BUSINESS WIRE)–Shopgate Inc., the leading SaaS retail app platform, adds Apple TV apps to their portfolio of shopping channels that already include iPhone, iPad and Android apps. Now, retailers can not only build apps designed for mobile devices, but also create retail apps designed for the recently launched Apple TV app store. With only ... Read More


Smart biking startup COBI grows to over 50 employees

February 25, 2016

The appointment of Sonja Glauert (37) as Head of Customer Relationship Management (CRM), previously Bosch eBike Service Manager, at the beginning of February brings an experienced eBike expert on board to enhance the COBI team. Christian Lortz (37) previously worked as Product Manager at SMART technologies and joined COBI as Senior Product Manager at the beginning of January. The engineering team has also been strengthened with the arrival of Ken Kölzer (29), former engineer at De’Longhi Braun Household, who joined COBI in February as Mechanical & Quality Engineer. … Read More


Phenex Announces Milestone Payment from Gilead as FXR drug candidate GS-9674 Enters Phase 1 Study

February 24, 2016

Phenex Pharmaceuticals AG (Phenex) today announced that the company will receive a milestone payment from Gilead Sciences, Inc. of Foster City, CA, U.S.A. for the initiation of a Phase 1 study for GS-9674, a novel, synthetic and non-steroidal FXR agonist, in non-alcoholic Steatohepatitis (NASH). In January 2015, Gilead acquired the Farnesoid X Receptor (FXR) program from Phenex, in a deal valued at 470 million US$. The FXR program is comprised of new small molecule therapeutics for the treatment of liver diseases, including NASH. … Read More


COBI raises a further 6.3 million Euros

January 22, 2016

COBI, the developer of the first smart control centre for bikes, has completed another round of financing. The company has received almost €6.3 million from Munich Venture Partners and other investors like Meinders & Elstermann – International Print & Mediaservices. This brings the total investment raised by the company to 12 million Euros. Creathor Venture and Capnamic Ventures, investors from the previous funding round in April 2015, have also increased their investments. COBI will use the fresh capital for internationalization as well as the development of further products. … Read More


Creathor invests in Happycar

January 19, 2016

December 2015 – Creathor Venture invests in Happycar, one of Europe’s fastest growing price comparison portals for rental cars. With more than 250 cooperation partners, the Hamburg-based company has one of the largest networks of partners in its industry. … Read More


Easybooking-CEO Hendrik Maat gives green light for further expansion

December 29, 2015

Hendrik Maat, CEO of zadego GmbH and its corporate branch easybooking, announces the opening of a long-planned new fourth office in Sopron, Hungary. This step has been taken earlier than planned due to a strong increase in customers in 2015 and is part of the very successful ongoing European rollout of the program. … Read More


Creathor partially exits Mila to Swisscom

December 2, 2015

Creathor Venture, one of the leading European Venture Capital firms, announces the partial exit of Mila AG, Berlin based sharing-economy platform to Swisscom, a leading Swiss ICT provider. The exit results in a substantial capital-gain for the Creathor-investors after a short holding-period.   Mila ( was founded in 2013 as a spin-off of the software ... Read More


News Republic’s Amazing Mobile Firehose

November 4, 2015

Gilles Raymond, News Republic’s founder and CEO, likes to use big numbers to describe his business: its app is available in 40 countries and 29 languages; news sourcing comes from 1500 separate deals with information providers, ranging from Reuters to The Guardian or Business Insider in the Western world, but also Hearst China, Sohu News (China), Baidu ... Read More


Precision Diagnostics “Made in Germany” Now Available In China

November 17, 2015

EndoPredict Spares Breast Cancer Patients Unnecessary Chemotherapy Cologne, November 12th, 2015 – The EndoPredict gene expression test developed and manufactured in Cologne now becomes available to breast cancer patients in the world’s most populous country: in China. This is made possible by a collaboration between the manufacturer, Sividon Diagnostics, and the Shanghai-based company Virchow Laboratories ... Read More


AYOXXA is Member of the International EYE-RISK Consortium

October 28, 2015

AYOXXA is Member of the International EYE-RISK Consortium LUNARIS™ multiplexing platform is applied in epidemiological studies for AMD   Cologne, October 22nd, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a ... Read More


CEVEC and BioLamina combine technology leadership

October 28, 2015

CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies   CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing BioLamina to further grow its leading high ... Read More


CEVEC: Scalable production of gene therapy vectors – an interview with Frank Ubags

October 28, 2015

Frank Ubags (CEO CEVEC Pharmaceuticals) is giving “insights from industry”. To see the full interview please click here: … Read More


Creathor Venture co-leads biggest Swiss Fintech financing round in Knip

October 26, 2015

Creathor Venture co-leads biggest Swiss Fintech financing round in Knip alongside Route 66 Ventures and QED with a total of USD 15.7 Million   Digital insurance manager Knip disrupts the b2c insurance broker market   Zurich, 26 October 2015 – With the Knip app, users can easily view and manage their portfolio of insurance policies ... Read More


Kyto receives a seven-figure sum

October 8, 2015

Berlin based IT company Kyto, founded in 2013, secured a seven digit investment. Besides the participation of new investor Müller Medien and significant financial support via the Pro FIT program of Investitionsbank Berlin (IBB), existing investors Projects A Ventures, Creathor Ventures and Bauer Venture Partners contributed to the new investment. Kyto is an international software ... Read More


CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP®GT technology

September 22, 2015

Agreement enables fully scalable, industrial lentivirus vector production Collaboration represents an important step in the roll-out of CEVEC’s strategy to position CAP®GT technology as the industrial standard for the production of lentiviral vectors for commercial gene therapy applications   Cologne, Germany, September 17, 2015 CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made ... Read More


AYOXXA BIOSYSTEMS appoints Dr. Gerald Möller as Chairman of the board

September 22, 2015

Cologne, September 14th, 2014 AYOXXA Biosystems GmbH, an international biotechnology company, announced that Dr. Gerald Möller has joined the company’s supervisory board as an independent board director and chairman of the board. With 40 years of experience in Pharma, Diagnostics and Biotech, Dr. Möller will guide AYOXXA’s strategic expansion from life science research into disease ... Read More


AYOXXA presenting LUNARIS™, a revolutionary technology for protein multiplexing

September 7, 2015

LUNARIS™ is AYOXXA’s unique  technology platform combining the robustness and quality of classical immunoassays with the performance of modern bead-based methods delivered on a solid surface. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple analytes in pg/mL concentrations, requiring minimal sample volumes.   AYOXXA offers a flexible and scalable system for 32 to ... Read More


CEVEC raises €4.5 million in a financing round to commercialize its leading CAP® based technologies

July 24, 2015

New and existing investors participated in this financing round CEVEC is setting new industry standards in glyco-optimized protein and gene therapy vector production with proprietary CAP®Go and CAP®GT technologies   Cologne, Germany, July 22, 2015 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced ... Read More


Creathor Venture, KfW & GMPVC successfully exit digital marketplace Danato to Gruner + Jahr

June 10, 2015

Munich/Bad Homburg, June 10, 2015 Creathor Venture, one of the leading European Venture Capital firms, announces the exit of Danato GmbH, the popular German e-commerce market place for gifts, to Gruner + Jahr. Danato ( was founded in 2011 by Jörg Überla and has been growing rapidly since. Supported by Creathor and the other investors ... Read More


Creathor invests in eHealth pioneer expanding in the US

May 6, 2015

eHealth-pioneer from Berlin raises $ 2.5 million from Creathor Venture, Partech, Stephan Schambach, Heilemann Ventures and existing investor Atlantic Labs. The investment will fuel its US expansion. Founded in 2013 by Simon Bolz and Dr. Simon Lorenz, the startup aims to digitize the communication between doctors and patients. After entering German-speaking markets beginning 2014, Klara ... Read More


Creathor Venture invests in COBI

April 15, 2015

Digital Pioneers develop first smart system for bicycles Creathor Venture, Capnamic Ventures and Iris Capital invest in German bike startup Capital to drive production and establishment of distribution, marketing and customer service   Frankfurt, April 15, 2015 – COBI, developer of the world’s smartest connected biking system, has completed one of the largest financing rounds ... Read More


HeidelbergCapital & Creathor Venture exit Accovion

April 13, 2015

US-based Clinipace Inc. acquires Accovion GmbH, Frankfurt Combined company has operations in 39 countries and employs nearly 1,000 staff Accovion CEO will head Clinipace’ European operations Heidelberg / Bad Homburg, April 13, 2015 – The independent Private Equity firms HeidelbergCapital and Creathor Venture together with former and current management and employees have sold their shares ... Read More


Creathor invests in Memorado, the globally leading brain training and cognitive science startup

March 30, 2015

Memorado raises $3.3M Series A to become global leader in cognitive enhancement   After growing to 1 million members in less than 6 months, Memorado now has over 3.5 million members just a year after launch. Series A funding led by Creathor Venture and Global Founders Capital with participation from existing investors Sunstone Capital and ... Read More


Creathor joins Series C round of Sinopsys Surgical

March 18, 2015

Bad Homburg, Germany and Boulder, Colorado (USA). Creathor has invested into Sinopsys Surgical, a clinical stage medical device company in Boulder, Colorado. Sinopsys has developed a stent device called the Sinopsys Lacrimal Stent. The lead indication for the stent is chronic rhinosinusitis with additional use in epiphora and potential in allergic rhinitis. Participants in this ... Read More


Karlheinz Schmelig (Partner) in interview with

March 18, 2015

For today’s article at “” Karlheinz Schmelig (Partner at Creathor Venture) and Dr. Maria Deeg were talking about trends, developments and founding location Rhein-Main. Click here to see whole interview! … Read More


News Republic won “Best Mobile Media and Publishing App” at MWC

March 5, 2015

News Republic won “Best Mobile Media and Publishing App” at Mobile World Congress 2015 in Barcelona. The award was presented by John Cleese on behalf of MWC’s 300 judges. Judges Comments: “Genuinely a step forward in terms of curation, intuitive design and connecting editorial interests for consumers. A pleasure to use.”   For more information ... Read More


EU research association proves the significance of the immune system in prognosis and treatment

March 3, 2015

As part of the EU RESPONSIFY research project, immune markers in tumours, which not only affect the prognosis of a breast cancer patient but also predict the response to certain treatments, were identified for the first time. In patients with HER2-positive or triple negative breast cancer (TNBC) in particular, the results of the research point the way ahead. These types of breast carcinomas are characterised by an aggressive progression of the disease, meaning that the development of new treatment strategies is particularly necessary for these Patient Groups. ...Read More


Testdroid Professional Services – A Dedicated Specialist for Automating Your App Testing

February 17, 2015

Testdroid Professional Services – A Dedicated Specialist for Automating Your App Testing Dear Testdroiders, As you might know, we’ve offered professional services for creating test scripts and integrating all Testdroid products into your continuous integration environments, build systems, various different tools and other scripts. Today, we’re launching a new service that will bring you even ... Read More


Deconstructing Continuous Quality Process for Mobile App Development

February 19, 2015

Deconstructing Continuous Quality Process for Mobile App Development Dear Testdroiders, Mobile app users and gamers are more demanding than ever before. According to McKinsey and their analysts, the application related revenues have reached $25 billion already in 2013 and are on the way to reach more than $70 billion by 2017. In this study, the ... Read More


Insiteo deploys its indoor positioning solution in Toulouse Blagnac Airport

February 9, 2015

Insiteo, the leader in indoor location and proximity marketing deployed its services in Toulouse-Blagnac Airport to empower the new mobile application released this month. The application, available for iPhone and Android devices, has been specifically designed for frequent flyers with an innovative “find-my-car” feature. Indeed, the parking lot is automatically stored in the application thanks ... Read More


Collaboration between AYOXXA and Singapore Eye Research Institute

February 9, 2015

Validation of new protein multiplexing technology platform in the ophthalmic domain Cologne and Singapore 03. February 2015 AYOXXA, an international biotech company with headquarters in Cologne, has signed an agreement with the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s ... Read More


Phenex Pharmaceuticals announces acquisition of its development program for non-alcoholoic steatohepatitis

February 4, 2015

Creathor’s portfolio company Phenex Pharmaceuticals announces acquisition of its development program for non-alcoholoic steatohepatitis (NASH) and other liver diseases by Gilead Sciences, Inc., for up to $470m January 7, 2015 – Bad Homburg, Ludwigshafen/Heidelberg, Foster City, CA Gilead Sciences, Inc. (Nasdaq: GILD) and Phenex Pharmaceuticals AG, a Creathor portfolio company, today announced the signing of ... Read More


Accovion launches new subsidiary in France

December 3, 2014

  Frankfurt / Eschborn, December 1, 2014 Accovion, a leading independent European full-service Contract Research Organization, headquartered in Frankfurt (Eschborn), Germany, announced today the establishement of a new subsidiary in Lyon, France, as it continues its expansion across Europe. Together with offices in Italy, Poland, Russia, Romania, Spain, Czech Republic and United Kingdom, Accovion is ... Read More


Creathor Venture sold its stake in Jaron GmbH to EQT funded digital media group UDG

July 2, 2011

Bad Homburg / Frankfurt am Main, June 2011. The international venture capital company Creathor Venture has successfully sold its shares in online marketing company Jaron GmbH. The digital media group UDG is an agency network for digital communication in Germany. The parties have agreed not to disclose any details of the transaction. With Creathor Venture ... Read More


Creathor Venture sells its stake in Doodle to Tamedia AG

May 12, 2011

The German Venture Capital company Creathor Venture has successfully sold its stake in Swiss scheduling platform Doodle AG. As part of this exit, the Swiss media company Tamedia AG acquired 49% of Doodle’s shares. Terms of this deal will not be disclosed. … Read More